Brief: Eloxx Pharmaceuticals Announces Final Data Assessment From Phase 2 Combination Clinical Trial Of ELX-02
14/06/2023 22:31
June 14 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS ANNOUNCES FINAL DATA ASSESSMENT FROM
PHASE
2 COMBINATION CLINICAL TRIAL OF ELX-02 IN CLASS 1 CYSTIC
FIBROSIS (CF) PATIENTS
* ELOXX PHARMACEUTICALS INC - ELX-02 WAS GENERALLY WELL
TOLERATED
IN TRIAL, WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS NOTED
* ELOXX PHARMACEUTICALS INC- ELX-02 TRIAL DEMONSTRATED
CLINICALLY
RELEVANT IMPROVEMENT IN PERCENT PPFEV1 BASED ON FINAL DATA
ASSESSMENT
Source text for Eikon: ID:nGNX4GlFjN
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome